Login to Your Account



NewCo News

GeNeuro Targeting Retrovirus Via MAbs in MS, Schizophrenia

By Marie Powers
Staff Writer

Wednesday, November 21, 2012
newco_news_resized.jpg

Spun out in 2006 from French diagnostics firm BioMérieux SA with the help of Swiss bioincubator Eclosion, GeNeuro SA has slowly but steadily progressed its monoclonal antibody (mAb) technology – initially to prevent the inflammatory and autoimmune cascades induced by the multiple sclerosis-associated retrovirus (MSRV).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription